Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Research Advance of BCR-ABL Mutation and the Efficacy of Second and Third Generation TKI in Chronic Myeloid Leukemia--Review].

Zhongguo shi yan xue ye xue za zhi - 1 Apr 2023

Zhou Li-Yua, Zhou Li-Yua

Abstract excerpt

The treatment of chronic myeloid leukemia (CML) was revolutionized with the advent of the first-generation tyrosine kinase inhibitors (TKIs), but drug resistance developed during treatment, leading to the development of the second-generation (dasatinib, nilotinib, and bosutinib) and third-generation (ponatinib) TKI. Compared with previous treatment regimens, specific TKI can significantly improve the response...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Dasatinib
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fusion Proteins, bcr-abl

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 37096538
DOI: 10.19746/j.cnki.issn.1009-2137.2023.02.040

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Research Advance of BCR-ABL Mutation and the Efficacy of Second and Third Generation TKI in Chronic Myeloid Leukemia--Review].PMID 37096538Read ↗

[Recent Advance of Newly Therapy for Chronic Myeloid Leukemia with BCR-ABLT315I Mutation--Review].Semantic proximity Read ↗

Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.Semantic proximity Read ↗

[Key points in second-line therapy for chronic myeloid leukemia].Semantic proximity Read ↗

ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.Semantic proximity Read ↗

MUTATIONAL STATUS AND TREATMENT EFFICACY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA.Semantic proximity Read ↗

Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?Semantic proximity Read ↗

[Clinical Analysis for 42 Imatinib-resistant Patients with Chronic Myelogenous Leukemia].Semantic proximity Read ↗

Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapySemantic proximity Read ↗

A review of the European LeukemiaNet recommendations for the management of CML.Semantic proximity Read ↗

Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a reviewSemantic proximity Read ↗

Tyrosine kinase inhibitors: the first decade.Semantic proximity Read ↗

Recent advances in Bcr-Abl tyrosine kinase inhibitors for overriding T315I mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.